Investor Hub

Access company performance, market insights, and strategic updates as Lunit drives long-term value through clinically validated, AI-powered cancer diagnostics and biomarker innovation.
Contact Investor Relations

Loading stock data...

Latest Updates

Annual Financial Statement

Annual Financial Statement

Presentations

Presentations

IR Letters

IR Letters

Disclosure

Disclosure

Lunit at a Glance

Lunit is advancing a smarter standard of cancer care through AI-powered diagnostics and biomarker analysis. Trusted by hospitals and biopharma leaders across 65+ countries, our solutions are FDA-cleared, clinically validated, and deployed at scale across 10,000+ global sites.

**Lunit INSIGHT MMG and Lunit INSIGHT DBT are FDA-cleared
**Lunit SCOPE is for Research Use Only. Not for use in diagnostic procedures

Lunit at a Glance
Lunit CEO, Brandon Beomseok Suh speaking at a podium.

A High-Growth, Purpose-Driven Investment

Global demand is accelerating for earlier cancer detection and more precise, data-driven treatment. Backed by clinical validation, regulatory approvals, and growing adoption across healthcare and biopharma sectors, Lunit is strategically positioned to deliver scalable innovation and long-term shareholder value.
Media Center

Media Center

Sustainability

Sustainability

Governance

Governance

Connect with Investor Relations

Connect with Investor Relations

If you have inquiries regarding Lunit’s financial performance, strategic direction, or ESG commitments, please contact our investor relations team.
Contact Investor Relations